Unique features of the mode of action of ET-743

Oncologist

Volumn 7, Issue 3, 2002, Pages 210-216

  D'Incalci, Maurizio ^a   Erba, Eugenio ^a   Damia, Giovanna ^a   Galliera, Emanuela ^a   Carrassa, Laura ^a   Marchini, Sergio ^a   Mantovani, Roberto ^b   Tognon, Gianluca ^a   Fruscio, Robert ^a   Jimeno, José ^c   Faircloth, Glynn T ^d  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c PHARMAMAR S A   (Spain)

^d PharmaMar USA Inc   (United States)

Author keywords

Anticancer drug; ET 743; Marine compound; Natural product

Indexed keywords

CELL DNA; CISPLATIN; DOXORUBICIN; HEAT SHOCK PROTEIN 70; PACLITAXEL; TRABECTEDIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CELL CYCLE; CLINICAL TRIAL; DNA REPAIR; DRUG DNA BINDING; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; HUMAN; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RHABDOMYOLYSIS; SOFT TISSUE SARCOMA; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; HUMANS; ISOQUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROISOQUINOLINES; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 18444404938     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-3-210     Document Type: Article

References (37)

1. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata
2. Molecular and crystal structures of ecteinascidins: Potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata
3. Progress in the acquisition of new marine-derived anticancer compounds: Development of ecteinascidin-743 (ET-743)
4. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients
5. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts
6. Ecteinascidin-743: A marine-derived compound in advanced, pretreated sarcoma patients - Preliminary evidence of activity
7. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors
8. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study
9. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies
10. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata
11. NMR-based model of an ecteinascidin 743-DNA adduct
12. Ecteinascidin 743: A minor groove alkylator that bends DNA toward the major groove
13. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent
14. Molecular basis for the DNA sequence selectivity of Ecteinascidin 736 and 743: Evidence for the dominant role of direct readout via hydrogen bonding
15. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA
16. Interference of transcriptional activation by the anti-neoplastic drug ecteinascidin-743
17. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
18. Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650
19. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
20. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticanceranti drug that selectively alkylates DNA in the minor groove
21. Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743
22. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA repair pathways
23. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression
24. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
25. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
26. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: Identification of ecteinascidin-743 as a potent cytotoxic agent
27. p73α overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line
28. ET-743 and cisplatin (DDP) show in vitro and in vivo synergy against human sarcoma and ovarian carcinoma cell lines
29. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells
30. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies
31. A phase I and pharmacokinetic (PK) study of ET-743 evaluating a 3 hours (h) intravenous (iv) infusion (I) in patients (pts) with solid tumors
32. Phase I and pharmacokinetic study of ET-743, a minor groove DNA binder, administrated weekly to patients with advanced cancer
33. Ecteinascidin-743 given as a 24 hour (H) intravenous continuous infusion (IVCI) every 3 weeks: Results of a Phase II trial in patients (PTS) with pretreated soft tissue sarcomas (PSTS)
34. Ecteinascidin-743 (ET-743) induces durable responses and promising 1-year survival rates in soft tissue sarcomas (STS): Final results of phase II and pharmacokinetic studies in the U.S.A.
35. ET-743 is an active drug in adult soft-tissue sarcoma: A STBSG-EORTC Phase II trial
36. Preliminary results of phase II study of ecteinascidin-743 (ET-743) with the 24 hour (H) continuous infusion (CI) Q3weeks schedule in pretreated advanced/metastatic breast cancer (A/MBC) patients (Pts)
37. Ecteinascidin 743 (ET-743) in ovarian cancer: Activity in xenografts and preliminary results of an ongoing study in patients failing platinum-taxanes